We are impressed by the quality of data delivered by the Olink technology with very small sample sizes. The application in the field of precision medicine is extremely promising.

Olink has developed a very innovative technology that has a simplicity approach to be able to measure large numbers of proteins. That’s a significant breakthrough for investigators to break into a field of diseases that you could not explore without this technology.

I am very pleased with the Olink methodology, which has revealed several new biomarkers in the CSF and plasma from patients with multiple sclerosis. It was of particular interest to be able to detect markers in plasma that reflect neuronal damage, including neurofilament light chains

Our work with Olink on plasma-based immuno-oncology (IO) applications has allowed the identification of tumor and immune changes associated with immune checkpoint inhibitor response/non-response.This is particularly exciting as we combine this technology with deep tumor-based analysis to understand tumor-immune interactions and establish predictive and/or monitoring tools for IO. The small volume required for Olink analysis is a game-changer as it allows multi-analyte assessment of samples and validation of findings by multiple orthogonal platforms.

Olink’s immunoassay panels are very useful tools for targeting and discovering protein dynamics in our longitudinal studies, such as the integrative personal omics profile (iPOP)

We have employed Olink panels in longitudinal deep phenotyping studies of over 5,000 individuals. We have found the data quality and reproducibility to be among the best of the high dimensional data strategies we have used.

The Olink panel provided some directions we wouldn’t have considered previously, and is a very appealing strategy for neuroscience projects hoping to identify novel CSF biomarkers

In profiling the immune systems of newborn children, the Olink panels allow us to maximize the amount of information extracted from a few microliters of plasma.

My interest in biomarkers grew in parallel to the growth of Olink. Back in 2014, when I first selected the Olink technology for an important  EU-funded program that I was coordinating, the company had only a handful of employees. Since then, Olink’s growth was amazing. Yet, they still  behave like partners, not simple providers. I have since recommended Olink to many international colleagues.